845910-14-7

Basic information

• Product Name: 1-amino-3-(4-methoxyphenyl)propan-2-ol
• Synonyms: 1-amino-3-(4-methoxyphenyl)propan-2-ol
• CAS NO: 845910-14-7
• Molecular Weight: 181.235
• Mol File: 845910-14-7.mol

Chemical Properties

• CAS DataBase Reference: 1-amino-3-(4-methoxyphenyl)propan-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-amino-3-(4-methoxyphenyl)propan-2-ol(845910-14-7)
• EPA Substance Registry System: 1-amino-3-(4-methoxyphenyl)propan-2-ol(845910-14-7)

Safety Data

• Hazardous Substances Data: 845910-14-7(Hazardous Substances Data)

Usage

Type of compound

Organic chemical compound

Derivative of

3-(4-methoxyphenyl)propan-1-amine

Structural modification

Added hydroxyl group at the second carbon position

Chiral center

Second carbon

Enantiomers

Exists as a pair of enantiomers

Industry use

Pharmaceutical industry

Application

Intermediate in the synthesis of various drugs and pharmaceuticals

Research and development

Potential applications for modulating and interacting with biological systems

Additional use

Chiral resolving agent for the separation of racemic mixtures

Upstream product

• 51410-45-8 estragole oxide 
• 845910-13-6 1-azido-3-(4-methoxy-phenyl)-propan-2-ol 

Downstream Products

• 845909-90-2 2-[2-hydroxy-3-(4-methoxy-phenyl)-propylamino]-3-methyl-5-naphthalen-2-yl-6-pyridin-4-yl-3H-pyrimidin-4-one 

Relevant articles and documents

Chemoselective Synthesis of Amines from Ammonium Hydroxide and Hydroxylamine in Continuous Flow

The chemoselective amination of alkyl bromides and chlorides with aqueous ammonia and hydroxylamine was achieved in continuous flow to produce primary ammonium salts and hydroxylamines in high yields. An in-line workup was designed to isolate the corresponding primary amine, which was also telescoped in further reactions, such as acylation and Paal-Knorr pyrrole synthesis. Monosubstituted epoxides are also compatible with the reaction conditions.

Substituted heterocyclic compounds and methods of use

The present invention relates to compounds having the general formula or a pharmaceutically acceptable salt thereof, wherein R1 is a saturated or unsaturated 5-, 6- or 7-membered, ring containing 0, 1, 2 or 3 atoms selected from N, O and S, whe